Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy

PHASE3CompletedINTERVENTIONAL

Enrollment

102

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

March 31, 2004

Conditions

ArthritisPsoriatic

Interventions

DRUG

adalimumab

40 mg adalimumab eow Week 0 - Week 12

DRUG

placebo for adalimumab

placebo eow Week 0 - Week 12